HIV postexposure prophylaxis in the 21st century

Emerging Infectious Diseases

Volumn 7, Issue 2, 2001, Pages 254-258

  Henderson, David K ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Building 10 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXY 3' HYDROXYMETHYLCYTIDINE; 2,3' DIDEOXY 3' HYDROXYMETHYLCYTIDINE; ANTIRETROVIRUS AGENT; LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

CELLULAR IMMUNITY; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE TRANSMISSION; DRUG EFFICACY; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; OCCUPATIONAL EXPOSURE; PATHOGENESIS; PROPHYLAXIS; T LYMPHOCYTE; TREATMENT OUTCOME; VERTICAL TRANSMISSION; VIRUS LOAD;

EID: 0035042566     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0702.010221     Document Type: Conference Paper

References (44)

1. Prophylactic zidovudine after occupational exposure to the human immunodeficiency virus: An interim analysis
2. Post-exposure chemoprophylaxis for occupational exposure to HIV-1: Current status and prospects for the future
3. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques
4. Low levels of HIV-1 infection in cutaneous dendritic cells promote extensive viral replication upon binding to memory CD4+ T cells
5. Chemoprevention of retroviral infection: Success is determined by virus inoculum strength and cellular immunity
6. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood
7. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids
8. Effect of zidovudine postexposure prophylaxis on the development of HIV- specific cytotoxic T-lymphocyte responses in HIV-exposed health care workers
9. Risk of nosocomial infection with human T-cell lymphotropic virus type III/lymphadenopathy-associated virus in a large cohort of intensively exposed health care workers
10. Prevention of simian immunodeficiency virus, SIV, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005
11. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine
12. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment
13. Potent efficacy of post-exposure prophylaxis (PEP) up to 72 hours after intra-vaginal exposure of pig-tailed macaques with a human-derived retrovirus (HIV-2)
14. Trends in perinatal transmission of HIV/AIDS in the United States
15. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment
16. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant
17. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric
18. Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1
19. Prevention of vertical HIV transmission: Additive protective effect of elective Cesarean section and zidovudine prophylaxis
20. Mother-to-child transmission of human immunodeficiency virus type 1: Influence of parity and mode of delivery
21. Reduction in the risk of vertical transmission of HIV-1 associated with treatment of pregnant women with orally administered zidovudine alone
22. Impact of zidovudine post-perinatal exposure prophylaxis (PPEP) on vertical HIV-1 transmission: A prospective cohort in four U.S. Cities
23. Interim analysis of early efficacy of three short ZDV/3TC combinations regimens to prevent mother-to-child transmission of HIV-1: The PETRA trial
24. Zidovudine-lamivudine for prevention of mother to child HIV-1 transmission
25. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
26. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa
27. Antiretroviral therapies in pregnancy: Maternal, fetal and neonatal effects
28. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomised controlled trial
29. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: A randomised trial
30. Diminution de la transmission mere-enfant
31. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus
32. A case-control study of HIV seroconversion in health care workers after percutaneous exposure
33. Postexposure treatment of HIV - Taking some risks for safety's sake
34. Postexposure prophylaxis for occupational exposure to HIV
35. Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis
36. HIV Transmission after an occupational exposure despite postexposure prophylaxis with a combination drug regimen
37. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
38. Adherence to protease inhibitors, HIV-1 load, and development of drug resistance in an indigent population
39. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy
40. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues
41. Sustained decrease in percutaneous injuries (PI) in temporal association with universal/standard precautions (UP/SP) and PI-reducing strategies (PIRS)
42. Percutaneous injury analysis: Consistent categorization, effective reduction methods, and future strategies
43. Eight-year analysis of percutaneous injuries: Categorization, effective reduction methods and future strategies
44. Temporal association between implementation of universal precautions and a sustained, progressive decrease in percutaneous exposures to blood